Journey Medical (DERM) Stock Overview
Focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
DERM Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Journey Medical Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.76 |
| 52 Week High | US$9.56 |
| 52 Week Low | US$5.06 |
| Beta | 0.82 |
| 1 Month Change | -4.20% |
| 3 Month Change | 1.17% |
| 1 Year Change | 45.32% |
| 3 Year Change | 426.10% |
| 5 Year Change | n/a |
| Change since IPO | -18.32% |
Recent News & Updates
Recent updates
Does Journey Medical (NASDAQ:DERM) Have A Healthy Balance Sheet?
Jan 14
US$11.50 - That's What Analysts Think Journey Medical Corporation (NASDAQ:DERM) Is Worth After These Results
Aug 15Is Journey Medical (NASDAQ:DERM) A Risky Investment?
Aug 12Is Journey Medical (NASDAQ:DERM) Using Too Much Debt?
Apr 01
Emrosi Launch Will Expand Rosacea Treatment Options
Emrosi's launch and favorable Phase III results are expected to boost revenue growth and enhance net margins through existing operations.A Piece Of The Puzzle Missing From Journey Medical Corporation's (NASDAQ:DERM) 26% Share Price Climb
Mar 25Journey Medical (NASDAQ:DERM) Has Debt But No Earnings; Should You Worry?
Feb 06Market Cool On Journey Medical Corporation's (NASDAQ:DERM) Revenues Pushing Shares 26% Lower
Jan 11Journey Medical Corporation (NASDAQ:DERM) Shares Fly 31% But Investors Aren't Buying For Growth
Oct 03Here's Why Journey Medical (NASDAQ:DERM) Has A Meaningful Debt Burden
Sep 14Does Journey Medical (NASDAQ:DERM) Have A Healthy Balance Sheet?
May 06Journey Medical Corporation (NASDAQ:DERM) Not Doing Enough For Some Investors As Its Shares Slump 31%
Mar 11Journey Medical Corporation's (NASDAQ:DERM) 33% Dip In Price Shows Sentiment Is Matching Revenues
Jan 18Journey Medical Corporation's (NASDAQ:DERM) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Nov 10Shareholder Returns
| DERM | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -1.1% | -0.5% | -2.3% |
| 1Y | 45.3% | 25.5% | 20.4% |
Return vs Industry: DERM exceeded the US Pharmaceuticals industry which returned 26.4% over the past year.
Return vs Market: DERM exceeded the US Market which returned 21.2% over the past year.
Price Volatility
| DERM volatility | |
|---|---|
| DERM Average Weekly Movement | 6.9% |
| Pharmaceuticals Industry Average Movement | 9.4% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: DERM has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: DERM's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 41 | Claude Maraoui | journeymedicalcorp.com |
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company’s marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Emrosi for the treatment of inflammatory lesions of rosacea, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis.
Journey Medical Corporation Fundamentals Summary
| DERM fundamental statistics | |
|---|---|
| Market cap | US$272.04m |
| Earnings (TTM) | -US$8.66m |
| Revenue (TTM) | US$59.40m |
Is DERM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DERM income statement (TTM) | |
|---|---|
| Revenue | US$59.40m |
| Cost of Revenue | US$20.16m |
| Gross Profit | US$39.24m |
| Other Expenses | US$47.90m |
| Earnings | -US$8.66m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.26 |
| Gross Margin | 66.05% |
| Net Profit Margin | -14.58% |
| Debt/Equity Ratio | 97.1% |
How did DERM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/12 15:28 |
| End of Day Share Price | 2026/03/12 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Journey Medical Corporation is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Scott Henry | Alliance Global Partners |
| Mayank Mamtani | B. Riley Securities, Inc. |
| Kalpit Patel | B. Riley Securities, Inc. |